FAQ

What is the difference between Mounjaro and Rybelsus?

Both Mounjaro and Rybelsus are safe and effective weight loss medications that help to reduce appetite, curb cravings and, when used alongside diet and lifestyle factors, help you to lose weight.

Rybelsus

• Rybelsus is a prescription medication containing the active ingredient semaglutide.
• Rybelsus is licensed for the treatment of type 2 diabetes but can be prescribed off-label as a weight loss medicine.
• It was developed by the pharmaceutical company Novo Nordisk
• It is part of the GLP-1 receptor agonist class of medicines.
• Semaglutide mimics our naturally occurring hormone, which is produced in the gut and is triggered by food intake.
• Rybelsus is an oral version of semaglutide that comes in tablet form.
• Rybelsus is to be taken once daily

Mounjaro

• Mounjaro contains the active ingredient Tirzepatide
• It is a revolutionary weight-loss injection that offers a clinically proven approach to managing obesity.
• It was developed by the pharmaceutical company Eli Lilly.
• It is a single use, once-weekly injectable treatment designed to regulate appetite and metabolism, providing a targeted solution for sustainable weight loss.
• Mounjaro is indicated for chronic weight management as an adjunct to a reduced-calorie diet and increased physical activity in adults with an initial BMI ≥30 kg/m² (obesity) or ≥27 kg/m² (overweight) in the presence of at least one weight-related comorbid condition.
• Mounjaro is a glucose-dependent insulinotropic polypeptide (GIP) receptor agonist and glucagon-like peptide-1 (GLP-1) receptor agonist. It is a first in a new class of treatments for weight loss and works by suppressing appetite, making you feel less hungry, resulting in weight loss.